Investment analysts at Goldman Sachs raised their price objective on shares of InterMune (NASDAQ:ITMN) to $40.00 in a note issued to investors on Wednesday, Analyst Ratings Network reports. Goldman Sachs’ price objective would suggest a potential upside of 30.51% from the company’s current price. InterMune Inc. (NASDAQ:ITMN) shares after opening at $37.26 moved to $38.29 on last trade day and at the end of the day closed at $34.60. Company price to sales ratio in past twelve months was calculated as 42.08 and price to cash ratio as 7.64. InterMune Inc. (NASDAQ:ITMN) showed a positive weekly performance of 7.82%.
Aastrom Biosciences Inc. (NASDAQ:ASTM) announced that its executives led by CEO and President Nick Colangelo will present at the Regen Med Investor Day 2014. Aastrom Biosciences Inc. (NASDAQ:ASTM) shares advanced 30.58% in last trading session and ended the day on $6.49. ASTM return on equity ratio is recorded as 87.90% and its return on assets is -288.30%. Aastrom Biosciences Inc. (NASDAQ:ASTM) yearly performance is -71.78%.
AVEO Oncology (NASDAQ:AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares moved up 7.19% in last trading session and was closed at $1.79, while trading in range of $1.71 – $1.88. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) year to date (YTD) performance is -2.19%.
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) is a biotechnology company. The Company’s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) weekly performance is 21.15%. On last trading day company shares ended up $1.26. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) distance from 50-day simple moving average (SMA50) is 24.98%. Analysts mean target price for the company is $14.00.